Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis

BACKGROUND AND OBJECTIVE: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily (q.d.) has demonstrated greater improvements in lung function, patient‐reported outcomes and lower exacerbation rates versus mono long‐acting muscarinic antagonists (LAMA) in chronic obstructive pulmonary disease (CO...

Descripción completa

Detalles Bibliográficos
Autores principales: Muro, Shigeo, Yoshisue, Hajime, Kostikas, Konstantinos, Olsson, Petter, Gupta, Pritam, Wedzicha, Jadwiga A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155057/
https://www.ncbi.nlm.nih.gov/pubmed/31339215
http://dx.doi.org/10.1111/resp.13651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155057/
https://www.ncbi.nlm.nih.gov/pubmed/31339215
http://dx.doi.org/10.1111/resp.13651

Ejemplares similares